(Health-NewsWire.Net, April 27, 2017 ) Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.
Publisher's analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020. For more information about this report: http://www.reportsweb.com/global-leukemia-therapeutics-market-2016-2020 Covered in this report The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors - F. Hoffmann-La Roche - Novartis - Bristol-Myers Squibb - AbbVie - Teva Pharmaceuticals
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001409083/sample
Other prominent vendors - Altor BioScience - Amgen - ARIAD Pharmaceuticals - Arno Therapeutics - Astex Pharmaceuticals - AstraZeneca - Baxter Healthcare - Bayer HealthCare - Bellicum Pharmaceuticals - Biogen - Boehringer Ingelheim - BioLineRx - Boston Biomedical - Celator Pharmaceuticals - Celgene - CTI BioPharma - Chroma Therapeutics - Chugai Pharmaceutical - Cyclacel Pharmaceuticals - Daiichi Sankyo - Eisai - Emergent BioSolutions - Erytech Pharma - Fate Therapeutics - Genzyme - Gilead Sciences - GlaxoSmithKline - iDD biotech - Immune Pharmaceuticals - Immunomedics - Infinity Pharmaceuticals - Innate Pharma - Jazz Pharmaceuticals - Juno Therapeutics - Karyopharm Therapeutics - Ligand Pharmaceuticals - MEDA Pharmaceuticals - MedImmune - Merck - Midas Pharma - Molecular Templates - MorphoSys - Nippon Shinyaku - Novo Nordisk - Onconova Therapeutics - Ono Pharmaceuticals - Orphan Europe - Otsuka - Pfizer - Portola Pharmaceuticals - Regeneron Pharmaceuticals - Sanofi - Sigma-Tau Pharmaceuticals - Stemline Therapeutics - Sunesis Pharmaceuticals - TG Therapeutics - TheraMAB - Tolero Pharmaceuticals - XEME Biopharma - Xencor - ZIOPHARM Oncology
Market driver - Technological advances in the monitoring of leukemia - For a full, detailed list, view our report
Market challenge - Limitations associated with current therapeutic options - For a full, detailed list, view our report
Market trend - Rise in the development of combination therapies - For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001409083/buying
Table of Contents: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Pipeline portfolio PART 06: Market landscape PART 07: Market segmentation by disease type PART 08: Global CLL therapeutics market PART 09: Global ALL therapeutics market PART 10: Global AML therapeutics market PART 11: Global CML therapeutics market PART 12: Geographical segmentation PART 13: Market drivers PART 14: Impact of drivers PART 15: Market challenges PART 16: Impact of drivers and challenges PART 17: Market trends PART 18: Vendor landscape PART 19: Key vendor analysis PART 20: Appendix
Purchase this Premium Research Report at: http://www.reportsweb.com/buy&RW0001409083/buy/2500 .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|